AXL upregulation has been shown to promote iMφs in a range of settings, including postmyocardial infarction (6, 24), nonalcoholic steatohepatitis (25), and renal fibrosis models (26–28). Here, AXL is linked to metabolic dysfunction-associated steatohepatitis.